BR0011440A - Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides - Google Patents
Derivados de rodanina e seu uso na inibição e formação de imagens de amilóidesInfo
- Publication number
- BR0011440A BR0011440A BR0011440-5A BR0011440A BR0011440A BR 0011440 A BR0011440 A BR 0011440A BR 0011440 A BR0011440 A BR 0011440A BR 0011440 A BR0011440 A BR 0011440A
- Authority
- BR
- Brazil
- Prior art keywords
- amyloid
- imaging
- derivatives
- rhodanine derivatives
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Patente de Invenção: "DERIVADOS DE RODANINA E SEU USO NA INIBIçãO E FORMAçãO DE IMAGENS DE AMILóIDES". A presente invenção proporciona um método de tratamento de mal de Alzheimer usando-se um composto da Fórmula (I) Também proporcionado é um método de inibição da agregação de proteínas amilóides usando-se um composto da Fórmula (I) e um método de formação de imagens de depósitos amilóides usando-se derivados de rodanina substituída.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13854599P | 1999-06-10 | 1999-06-10 | |
PCT/US2000/015072 WO2000076988A1 (en) | 1999-06-10 | 2000-05-31 | Rhodanine derivatives and their use in inhibiting and imaging amyloids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011440A true BR0011440A (pt) | 2002-03-19 |
Family
ID=22482518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011440-5A BR0011440A (pt) | 1999-06-10 | 2000-05-31 | Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1192144A1 (pt) |
JP (1) | JP2003502321A (pt) |
AU (1) | AU5455400A (pt) |
BR (1) | BR0011440A (pt) |
CA (1) | CA2370316A1 (pt) |
MX (1) | MXPA01009863A (pt) |
TR (1) | TR200103561T2 (pt) |
WO (1) | WO2000076988A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
EP1505970A1 (en) | 2002-05-10 | 2005-02-16 | QLT Inc. | Methods of using thiazolidine derivatives to treat cancer or inflammation |
JP2005535593A (ja) * | 2002-05-17 | 2005-11-24 | キューエルティー インコーポレーティッド | チアゾリジンジチオン誘導体の使用方法 |
AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
EP1622613A4 (en) * | 2003-05-14 | 2008-04-02 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US20060106077A1 (en) * | 2003-07-18 | 2006-05-18 | Pintex Pharmaceuticals, Inc. | Pin1-Modulating compounds and methods of use thereof |
JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Adおよび関連状態の治療のためのピペラジン誘導体 |
US20100041653A1 (en) * | 2008-08-15 | 2010-02-18 | Burnham Institute For Medical Research | Composition and methods for the design and development of metallo-enzyme inhibitors |
WO2011077751A1 (ja) * | 2009-12-25 | 2011-06-30 | キヤノン株式会社 | 中枢神経系組織標識用組成物、中枢神経系組織の標識方法、及び中枢神経系組織標識用組成物を用いたスクリーニング方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0915090A1 (en) * | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
-
2000
- 2000-05-31 EP EP00939472A patent/EP1192144A1/en not_active Withdrawn
- 2000-05-31 BR BR0011440-5A patent/BR0011440A/pt not_active IP Right Cessation
- 2000-05-31 AU AU54554/00A patent/AU5455400A/en not_active Abandoned
- 2000-05-31 JP JP2001503846A patent/JP2003502321A/ja active Pending
- 2000-05-31 WO PCT/US2000/015072 patent/WO2000076988A1/en not_active Application Discontinuation
- 2000-05-31 MX MXPA01009863A patent/MXPA01009863A/es unknown
- 2000-05-31 TR TR2001/03561T patent/TR200103561T2/xx unknown
- 2000-05-31 CA CA002370316A patent/CA2370316A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1192144A1 (en) | 2002-04-03 |
JP2003502321A (ja) | 2003-01-21 |
TR200103561T2 (tr) | 2002-04-22 |
MXPA01009863A (es) | 2002-05-06 |
AU5455400A (en) | 2001-01-02 |
WO2000076988A1 (en) | 2000-12-21 |
CA2370316A1 (en) | 2000-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR6530A (es) | Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina | |
NO2005024I1 (no) | Heksylaminolevulinat, eventuelt i form av et salt,fortinnsvis heksylaminolevulinathydroklorid | |
BR0112000A (pt) | Amina, composto, álcool, epóxido, cetona, azida, composição, uso de uma amina, métodos de tratamento de um paciente, de inibição da atividade da beta-secretase, de clivagem da proteìna precursora de amilóide e da produção de peptìdeo amilóide e de placa beta-amilóide em um animal, de tratamento ou prevenção de uma doença distinguida por depósitos de beta-amilóide no cérebro e de produção de um complexo de beta-secretase, e, kit | |
ATE314343T1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
NO995088D0 (no) | Alkyl, alkenyl og alkynyl krysamin G derivater for för-döden-diagnose av Alzheimers sykdom og in vivo avbildning og hindring av amyloidavsetning | |
DK0485045T3 (da) | Mono-N-substituerede 1,4,7,10-tetraazacyclododecanderivater, fremgangsmåde til fremstilling deraf samt farmaceutiske midler | |
EP1797878A3 (en) | Benzothiazole derivatives | |
ATE343562T1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
BR0011728A (pt) | Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide | |
CY1110448T1 (el) | Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
RU93005056A (ru) | Новое диаминовое соединение и церебральное защитное лекарственное средство на его основе | |
BR0011440A (pt) | Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides | |
BR0010802A (pt) | Antagonistas de receptor il-8 | |
IS8096A (is) | Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum | |
BR0110519A (pt) | Método para inibir a agregação de proteìnas amilóides e formar imagens dos depósitos de amilóides usando derivados de aminoindano | |
BR0011441A (pt) | Derivados de rodanina para uso em um método de inibição da agregação da proteìna amilóide e formação de imagens de depósitos amilóides | |
ATE188217T1 (de) | 1,2,3,4,10,14b-hexahydrodibenzo-c,f)pyrazino-1, - a)azepino-derivate | |
ATE213410T1 (de) | Diclofenac/gamma-cyclodextrin klathrat komponente | |
ES2128701T3 (es) | Derivados triciclicos y su uso en productos farmaceuticos. | |
DK0588797T3 (da) | N- 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl carbonyl aminosyrer nyttige ved behandling af osteoartikulære lidelser | |
NO971899D0 (no) | Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom | |
KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
KR930703013A (ko) | 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제 | |
RU94013445A (ru) | Новое соединение, лейстродуксин н, способ его получения и терапевтическая композиция |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 8O E 9O ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |